The global market study pneumococcal conjugate (PCV) market is ~$8 billion per year, and Vaxcyte Inc (NASDAQ:PCVX) estimates it will grow to ~$12 billion in the next few years.  The market is currently split into 25% adults / 75% infants. Needham writes that Vaxcyte’s management expects this split to morph into 60% adults /40% infants over the next 3-5 years, with adults representing the bulk of the growth opportunity.  In the U.S., there’s discussion about lowering the age for vaccinations to 50 and above, potentially doubling the adult market. With around 60 million adults aged 65 and above and approximately 120 million aged 50 and above, this shift ...